Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: A a dose-escalation Phase I study in children and adolescent with relapsed or refractory leukemia.
    Active substance: arsenic trioxide
    Study summary document link (including results): Trisenox T99080.xls
    View full study record
    Document reference: 47199
    Study title: Phase II Study of Arsenic Trioxide in Neuroblastoma and other Pediatric solid tumors.
    Active substance: arsenic trioxide
    Study summary document link (including results): Trisenox CTI 1059.xls
    View full study record
    Document reference: 39686
    Study title: The CALGB study ( C9710) was designed primarily to test the hypothesis that arsenic trioxide, when added to consolidation therapy in the treatment of newly diagnosed patients, improves patients’ event-free survival in the newly diagnosed setting. In addition, this study evaluated the benefits and risks of 2 maintenance therapy regimens (ATRA versus ATRA plus mercaptopurine [6-MP]/methotrexate [MTX]), as well as the prognostic significance of CD56 expression.
    Active substance: arsenic trioxide
    Study summary document link (including results): TrisenoxCALGBC9710.xls
    View full study record
    Document reference: 47200
    Study title: Children's Cancer Group Study CCG-1961 : Asparaginase antibodies and asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21882
    Study title: COALL 82
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21883
    Study title: COALL 85
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21884
    Study title: COALL 89
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21885
    Study title: COALL 92
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21886
    Study title: COG study : Outcome of children with Bprecursor ALL registered on Pediatric Oncology Group 8602 who switched to Erwinia due to an allergy to the E.coli product
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21957
    Study title: Comparison of chemotherapy dose modifications in obese and nonobese pediatric patients with acute lymphoblastic leukemia (ALL).
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21961
    Study title: Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac : Pharmacokinetics, pharmacodynamics, formation of Antibodies and influence on the coagulation system
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21954
    Study title: Comparison of the efficacy of chemotherapeutic drug regimens using E.coli asparaginase or Erwinia asparaginase in childhood ALL
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21960
    Study title: DCLSG ALL-8 study: BFM-oriented treatement for children with acute lymphoblastic leukemia without cranial irradiation and treatement reduction for standard risk patients
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21964
    Study title: DFCI ALL 81-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21890
    Study title: DFCI ALL 85-01 study: Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21891
    Study title: DFCI ALL 87-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21892
    Study title: DFCI ALL 91-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21893
    Study title: DFCI ALL 95-01: Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21920
    Study title: Effects of glucocorticoids, E.coli-and Erwinia l-asparaginase on hemostatic proteins in children with ALL
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21915
    Study title: EORTC-CLG trial 5881: Comparison of E.coli and Erwinia asparaginase in the treatment of childhood lymphoid malignancies
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21881
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 15:29:33 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA